Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia
Flinn I, Patel M, Kahl BS, et al.
Key Points:
IPI-145, an orally bio-available, small molecule with potent PI3K-δ,γ inhibitory property in clinical development
Preliminary safety data from phase I study of patients with relapsed/refractory (R/R) CLL indicated compound was well tolerated
Promising clinical activity seen across range of doses examined
IPI-145 at 25 mg BID is the recommended dose for subsequent studies
Implications:
- Targeting PI3K may represent novel treatment strategy in patients with CLL
View the original abstract on the ASH website.
